Project cooperationUpdated on 25 November 2025
Tackling antibiotic resistance using nano-poly-pharmacology
CEO at THERIOPHARM
Wavre, Belgium
About
Validated on a sepsis murin model using pan-resistant Acinetobacter baumannii.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Similar opportunities
Project cooperation
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Hakim Ferria
European projects manager at INSA Lyon
Lyon, France
Project cooperation
FAIR & EHDS-Aligned Data Infrastructures for Health Research and Innovation
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Theo Zacharis
Executive Director / Founder at Kinesis Innovation Center
Athens, Greece
Project cooperation
Organ on chips, organoids and other NAMs for biomedical research
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Joude Cachoux
Business Development Manager, PharmD, MPH at LEITAT
Barcelona, Spain